1. Pyrazolone-Based Zn(II) Complexes Display Antitumor Effects in Mutant p53-Carrying Cancer Cells.
- Author
-
Xhafa S, Di Nicola C, Tombesi A, Pettinari R, Pettinari C, Scarpelli F, Crispini A, La Deda M, Candreva A, Garufi A, D'Orazi G, Galindo A, and Marchetti F
- Subjects
- Humans, Cell Line, Tumor, Mutation, Schiff Bases chemistry, Schiff Bases pharmacology, Schiff Bases chemical synthesis, Structure-Activity Relationship, Drug Screening Assays, Antitumor, Models, Molecular, Crystallography, X-Ray, Pyrazolones pharmacology, Pyrazolones chemistry, Pyrazolones chemical synthesis, Tumor Suppressor Protein p53 metabolism, Tumor Suppressor Protein p53 genetics, Zinc chemistry, Zinc pharmacology, Zinc metabolism, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Antineoplastic Agents chemical synthesis, Coordination Complexes pharmacology, Coordination Complexes chemistry, Coordination Complexes chemical synthesis
- Abstract
The synthesis and characterization of nine Schiff bases of pyrazolone ligands HL
n ( n = 1-9) and the corresponding zinc(II) complexes 1 - 9 of composition [Zn(Ln )2 ] ( n = 1-9) are reported. The molecular structures of complexes 2 , 3 , 4 , 8 , and 9 were determined by single-crystal X-ray diffraction analysis, highlighting in all cases a distorted tetrahedral geometry around the Zn(II) ion. Density functional theory studies are performed on both the HLn ligands and the derived complexes. A mechanism of dissociation and hydrolyzation of the coordinated Schiff base ligands is suggested, confirmed experimentally by powder X-ray diffraction study and photophysical studies. Complexes 1-9 were investigated in vitro as anticancer agents, along with mutant p53 (mutp53) protein levels in human cancer cell lines carrying R175H and R273H mutp53 proteins. Only those complexes with the highest Zn(II) ion release via dissociation have shown a significant cytotoxic activity with reduction of mutp53 protein levels.- Published
- 2024
- Full Text
- View/download PDF